Nektar Therapeutics
NKTR
$75.06
$2.853.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -43.89% | -32.79% | -19.56% | -3.24% | 9.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.89% | -32.79% | -19.56% | -3.24% | 9.22% |
| Cost of Revenue | -- | -73.40% | -67.33% | -37.14% | -9.13% |
| Gross Profit | -18.47% | -13.50% | 13.33% | 18.52% | 20.21% |
| SG&A Expenses | -10.52% | -3.01% | -2.04% | 5.84% | -0.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.54% | -13.13% | -6.22% | 1.91% | 1.33% |
| Operating Income | -0.66% | -0.34% | -2.98% | -5.41% | 3.92% |
| Income Before Tax | -37.76% | 28.01% | 30.76% | 24.33% | 56.85% |
| Income Tax Expenses | 42.26% | -4,655.56% | -388.61% | 11.63% | -19.50% |
| Earnings from Continuing Operations | -37.92% | 28.26% | 30.95% | 24.34% | 56.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.92% | 28.26% | 30.95% | 24.34% | 56.91% |
| EBIT | -0.66% | -0.34% | -2.98% | -5.41% | 3.92% |
| EBITDA | -3.36% | -3.85% | -6.59% | -8.83% | 1.48% |
| EPS Basic | -17.07% | 36.87% | 35.55% | 31.00% | 60.01% |
| Normalized Basic EPS | 7.13% | 1.87% | -4.66% | -4.09% | 6.74% |
| EPS Diluted | -16.94% | 36.80% | 35.48% | 30.93% | 59.97% |
| Normalized Diluted EPS | 6.76% | 2.25% | -4.28% | -3.72% | 7.11% |
| Average Basic Shares Outstanding | 22.90% | 13.97% | 7.16% | 9.52% | 8.23% |
| Average Diluted Shares Outstanding | 22.32% | 14.45% | 7.65% | 10.02% | 8.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |